Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 12/20 | 0.39 |
| ▸ | CTSK | P43235 | 11/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CTSL | P07711 | 2/20 | 0.35 |
| ▸ | CTSB | P07858 | 2/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL583479 | 1.00 | CTSS (0.39) | CTSSCTSKCYP2D6CTSLCTSB | |
| SCHEMBL6157182 | 0.86 | CYP2D6 (0.41) | CTSSCTSKCYP2D6CTSLCTSB | |
| SCHEMBL8969812 | 0.86 | CYP2D6 (0.41) | CTSSCTSKCYP2D6CTSLCTSB | |
| SCHEMBL27867336 | 0.83 | CTSS (0.37) | CTSSCTSKCYP2D6CTSLCTSB | |
| SCHEMBL29133366 | 0.83 | MGAM (0.35) | — | |
| SCHEMBL1171593 | 0.80 | CYP2D6 (0.41) | CTSKCYP2D6HDAC3HDAC1HDAC2 | |
| SCHEMBL1135983 | 0.80 | CYP2D6 (0.41) | CTSKCYP2D6HDAC3HDAC1HDAC2 | |
| SCHEMBL16903727 | 0.80 | CYP2D6 (0.41) | CTSSCTSKCYP2D6HDAC3HDAC1 | |
| SCHEMBL27923564 | 0.80 | CYP2D6 (0.41) | CTSSCTSKCYP2D6HDAC3HDAC1 | |
| SCHEMBL711473 | 0.79 | CYP2D6 (0.42) | CTSSCTSKCYP2D6CTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114634944-A | Method for applying co-expression vector to preparation of atorvastatin intermediate | 江苏阿尔法药业有限公司 | 2022-06-17 | — | — | CN | claimed |
| EP-1727795-B1 | PROCESS FOR THE PRODUCTION OF ATORVASTATIN CALCIUM IN AMORPHOUS FORM | RANBAXY LAB LTD (IN) | 2012-02-15 | — | — | EP | claimed |
| US-7994343-B2 | Process for the production of atorvastatin calcium in amorphous form | RANBAXY LABORATORIES LIMITED (IN) | 2011-08-09 | — | — | US | claimed |
| EP-1963516-B1 | METHOD FOR THE ENANTIOSELECTIVE ENZYMATIC REDUCTION OF HYDROXYKETO COMPOUNDS | IEP GMBH (DE) | 2011-02-23 | — | — | EP | claimed |
| US-20100197941-A1 | Process for the production of atorvastatin calcium in amorphous form | RANBAXY LABORATORIES LIMITED (IN) | 2010-08-05 | — | — | US | claimed |
| EP-1659110-A1 | Process for the production of atorvastatin calcium un amorphous form | Ranbaxy Laboratories Limited (IN) | 2006-05-24 | — | — | EP | claimed |
| EP-1577297-A1 | Process for the production of atorvastatin calcium in amorphous form | RANBAXY LABORATORIES, LTD. (IN) | 2005-09-21 | — | — | EP | claimed |
| US-20250368641-A1 | QUINOLINE COMPOUNDS AS INHIBITORS OF KRAS | INCYTE CORP (US) | 2025-12-04 | — | — | US | disclosed |
| US-12441727-B2 | Tricyclic compounds as inhibitors of KRAS | INCYTE CORPORATION (US) | 2025-10-14 | — | — | US | disclosed |
| US-12441742-B2 | Naphthyridine compounds as inhibitors of KRAS | INCYTE CORPORATION (US) | 2025-10-14 | — | — | US | disclosed |
| US-12378243-B2 | Quinoline compounds as inhibitors of KRAS | INCYTE CORPORATION (US) | 2025-08-05 | — | — | US | disclosed |
| US-20250188073-A1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS | INCYTE CORP (US) | 2025-06-12 | — | — | US | disclosed |
| EP-4548918-A2 | TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS | Incyte Corporation (US) | 2025-05-07 | — | — | EP | disclosed |
| US-5155251-A | Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate | WARNER-LAMBERT COMPANY (US) | 1992-10-13 | — | — | US | disclosed |
| US-5155251-A | Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate | WARNER-LAMBERT COMPANY (US) | 1992-10-13 | — | — | US | disclosed |
| US-5149837-A | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis | WARNER-LAMBERT COMPANY (US) | 1992-09-22 | — | — | US | disclosed |
| US-5124482-A | Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis | WARNER-LAMBERT COMPANY (US) | 1992-06-23 | — | — | US | disclosed |
| US-5097045-A | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis | WARNER-LAMBERT COMPANY (US) | 1992-03-17 | — | — | US | disclosed |
| US-5003080-A | Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis | WARNER-LAMBERT COMPANY (US) | 1991-03-26 | — | — | US | disclosed |
| EP-0330172-A2 | Improved process for trans-6-[2-(substituted-pyrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis | WARNER-LAMBERT COMPANY (US) | 1989-08-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12441727-B2 | Tricyclic compounds as inhibitors of KRAS | KRAS, NRAS, HRAS | CTSS 2083/4885CTSK 1576/4885CYP2D6 3160/4885 |
| US-12441742-B2 | Naphthyridine compounds as inhibitors of KRAS | KRAS, NRAS, HRAS | CTSS 2289/4885CTSK 1637/4885CYP2D6 2338/4885 |
| US-12378243-B2 | Quinoline compounds as inhibitors of KRAS | KRAS, NRAS, HRAS | CTSS 2184/4885CTSK 1544/4885CYP2D6 2530/4885 |
| US-20100197941-A1 | Process for the production of atorvastatin calcium in amorphous form | HMGCR, CACYBP, SARAF | CTSS 1464/4885CTSK 666/4885CYP2D6 1750/4885 |
| US-20250188073-A1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS | KRAS, NRAS, HRAS | CTSS 1632/4885CTSK 1218/4885CYP2D6 2925/4885 |
| US-20250368641-A1 | QUINOLINE COMPOUNDS AS INHIBITORS OF KRAS | KRAS, NRAS, HRAS | CTSS 2184/4885CTSK 1544/4885CYP2D6 2530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.